CD56 (NCAM) Monoclonal Antibody (CMSSB), APC, eBioscience™, Invitrogen™

Description

• Description: This CMSSB monoclonal antibody reacts with human CD56, also known as Neural Cell Adhesion Molecule (NCAM)
• CD56 is a highly glycosylated transmembrane molecule expressed by neurons and plays a role in the homotypic adhesion of neural cells
• In the hematopoietic system, CD56 is expressed on NK cells and a subset of T cells referred to as NKT cells
• Staining with CMSSB does not block binding of MEM188 or CB56
• Applications Reported: This CMSSB antibody has been reported for use in flow cytometric analysis
• Applications Tested: This CMSSB antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.125 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD56 (NCAM, neural cell adhesion molecule) is a transmembrane glycoprotein of the immunoglobulin family that serves as an adhesive molecule and is ubiquitously expressed in the nervous system in isoforms ranging from 120-180 kDa
• CD56 is found on T cells and NK cells, and is involved in cell migration, axonal growth, pathfinding and synaptic plasticity
• Polysialic modification results in reduction of CD56-mediated cell adhesion
• Through its extracellular region, CD56 mediates homophilic and heterophilic interactions by binding extracellular matrix components such as laminin and integrins
• CD56 is expressed on most neuroectodermal derived cell lines, tissues and neoplasms such as retinoblastoma, medulloblastoma, astrocytomas and neuroblastoma
• Further, CD56 is a widely used neuroendocrine marker with a high sensitivity for neuroendocrine tumors and ovarian granulosa cell tumors
• Diseases associated with CD56 dysfunction include rabies and blastic plasmacytoid dendritic cell neoplasms.